news
Clostridioides difficile vaccine shows promise in Phase III trial
Pfizer’s investigational C. difficile vaccine was shown to reduce the duration and severity of disease, but not prevent primary C. difficile infection.
List view / Grid view
Clostridioides difficile
article
How to overcome barriers in the adoption of microbiome-based therapies
This article from the global consulting firm Charles River Associates (CRA) describes how manufacturers must address and overcome three key barriers hindering progress in the microbiome sector and the optimal strategies needed to demonstrate the value of microbiome-based therapies in successful commercialisation.
article
Microbiome therapeutic development boosted by metabolomics
There is a growing adoption of metabolomics to support drug discovery and development. Metabolomics involves the comprehensive analysis of metabolites in biological specimens. As such, it is commonly used for the discovery and validation of biomarkers that can support critical decisions in the drug development process. In this article, Christopher…
